B·R·A·H·M·S RECEIVES FDA CLEARANCE TO MARKET AUTOMATED PROCALCITONIN (PCT) TEST

More Sensitive PCT Test Helps Improve Management of Sepsis

BRAHMS Kryptor compact

ANNAPOLIS, Maryland (April 8, 2008). B·R·A·H·M·S USA, Inc today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its patented Procalcitonin (PCT) Kryptor® test. The automated test will be used in critically ill patients on the first day of ICU admission as an aid to assess their risk for progression to severe sepsis and septic shock. more